Juliane Farthmann1, A Hanjalic-Beck2, J Veit3, B Rautenberg3, E Stickeler4, T Erbes3, M Földi5, A Hasenburg3. 1. Department of Gynecology and Obstetrics, University Medical Center Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany. juliane.farthmann@uniklinik-freiburg.de. 2. Centre of Gynecological Endocrinology and Reproductive Medicine Freiburg (CERF), Freiburg, Germany. 3. Department of Gynecology and Obstetrics, University Medical Center Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany. 4. Department of Gynecology and Obstetrics, University Medical Hospital Aachen, Aachen, Germany. 5. Foeldiklinik, Hinterzarten, Germany.
Abstract
PURPOSE: In this prospective trial, we evaluated the influence of chemotherapy for breast cancer on women's health-related quality of life (HR-QoL), sexual function, and mental status. METHODS: The patients completed validated questionnaires on HR-QoL, sexual function, and depression before, during, and at the end and finally 6 months after chemotherapy. Special attention was paid to possible differences between pre- and postmenopausal patients. RESULTS: Between 2008 and 2012, 79 patients were enrolled in the trial (mean age 47.46 years). Premenopausal participants were 63.3 %. Sexual activity dropped from 71.9 % before chemotherapy to a minimum of 47 % at the end of chemotherapy. A similar effect was seen for pleasure and discomfort. Depression values were the highest at the beginning of chemotherapy, with spontaneous improvement in many patients during the course of time. HR-QoL and global health status both increased 6 months after therapy. For almost all parameters, changes were more obvious in pre- than in postmenopausal patients. CONCLUSIONS: In a close monitoring, we observed significant changes in HR-QoL, depression, and sexual function in breast cancer patients. Special attention needs to be paid to premenopausal patients. The knowledge of effective recovery and spontaneous improvement of HR-QoL in spite of still impaired sexuality are important information in counseling both pre- and postmenopausal patients with diagnosis of breast cancer prior to upcoming therapy.
PURPOSE: In this prospective trial, we evaluated the influence of chemotherapy for breast cancer on women's health-related quality of life (HR-QoL), sexual function, and mental status. METHODS: The patients completed validated questionnaires on HR-QoL, sexual function, and depression before, during, and at the end and finally 6 months after chemotherapy. Special attention was paid to possible differences between pre- and postmenopausal patients. RESULTS: Between 2008 and 2012, 79 patients were enrolled in the trial (mean age 47.46 years). Premenopausal participants were 63.3 %. Sexual activity dropped from 71.9 % before chemotherapy to a minimum of 47 % at the end of chemotherapy. A similar effect was seen for pleasure and discomfort. Depression values were the highest at the beginning of chemotherapy, with spontaneous improvement in many patients during the course of time. HR-QoL and global health status both increased 6 months after therapy. For almost all parameters, changes were more obvious in pre- than in postmenopausal patients. CONCLUSIONS: In a close monitoring, we observed significant changes in HR-QoL, depression, and sexual function in breast cancerpatients. Special attention needs to be paid to premenopausal patients. The knowledge of effective recovery and spontaneous improvement of HR-QoL in spite of still impaired sexuality are important information in counseling both pre- and postmenopausal patients with diagnosis of breast cancer prior to upcoming therapy.
Entities:
Keywords:
Breast cancer; Depression; Quality of life; Sexual function
Authors: Lari Wenzel; Israel DeAlba; Rana Habbal; Brenda Coffey Kluhsman; Diane Fairclough; Linda U Krebs; Hoda Anton-Culver; Ross Berkowitz; Noreen Aziz Journal: Gynecol Oncol Date: 2005-05 Impact factor: 5.482
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Nancy K Janz; Christopher R Friese; Yun Li; John J Graff; Ann S Hamilton; Sarah T Hawley Journal: J Cancer Surviv Date: 2013-11-13 Impact factor: 4.442
Authors: Andrea Vodermaier; Wolfgang Linden; Katerina Rnic; Sandra N Young; Alvina Ng; Nina Ditsch; Robert Olson Journal: Breast Cancer Res Treat Date: 2013-12-13 Impact factor: 4.872
Authors: Karen Roberts; Travis Chong; Emma Hollands; Jason Tan; Ganendra Raj Kader Ali Mohan; Paul A Cohen Journal: Support Care Cancer Date: 2019-05-18 Impact factor: 3.603
Authors: Fleur Wiggenraad; Kate A Bolam; Sara Mijwel; Elsken van der Wall; Yvonne Wengström; Renske Altena Journal: Integr Cancer Ther Date: 2020 Jan-Dec Impact factor: 3.279
Authors: Natalia Gondim de Almeida; Tish M Knobf; Marcos Renato de Oliveira; Marina de Góes Salvetti; Mônica Oliveira Batista Oriá; Ana Virginia de Melo Fialho Journal: Asia Pac J Oncol Nurs Date: 2020-01-14
Authors: Lucía Morales-Sánchez; Violeta Luque-Ribelles; Paloma Gil-Olarte; Paula Ruiz-González; Rocío Guil Journal: Int J Environ Res Public Health Date: 2021-02-09 Impact factor: 3.390